Abby Hardy, Author at BioTuesdays

Developments

Enanta Pharma reports topline results from Phase 2a RSV trial

Enanta Pharmaceuticals (NASDAQ:ENTA) reported that, compared with placebo, EDP-938 significantly reduced viral load and resolved clinical symptoms in healthy adults infected with respiratory syncytial virus (RSV).

June 14, 2019

Developments

Karyopharm Therapeutics reports new selinexor combination data in multiple myeloma

Karyopharm Therapeutics (NASDAQ:KPTI) provided new and updated data from its Phase 1b/2 study evaluating selinexor and dexamethasone in combination with standard approved multiple myeloma (MM) therapies.

June 14, 2019

Developments

InflaRx treats first pyoderma gangraenosum patient in Phase 2a trial

InflaRx (NASDAQ:IFRX) treated the first patient in a Phase 2a trial of IFX-1, an injectable antibody drug, in pyoderma gangraenosum (PG) patients.

June 13, 2019

Developments

ContraVir Pharma CRV431 data published in PLOS ONE

ContraVir Pharmaceuticals (NASDAQ:CTRV) CRV431 data from an experimental model of hepatitis B virus (HBV) has been published in the peer-reviewed journal, PLOS ONE.

June 11, 2019

Developments

Helius Medical PoNS study on brain activity in peer-reviewed journal

Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) reported that a scientific paper entitled, “Human Translingual Neurostimulation Alters Resting Brain Activity in High-density EEG,” was published in the latest edition...

June 11, 2019

Developments

vTv Therapeutics reports positive topline results from Phase 2 diabetes trial

vTv Therapeutics (NASDAQ:VTVT) reported positive topline results from its Phase 2 trial of TTP399 in Type 1 diabetes (T1D) patients.

June 6, 2019

Developments

ContraVir Pharma sets stage for CRV431 development in NASH with positive results in second model of liver fibrosis

ContraVir Pharmaceuticals (NASDAQ:CTRV) reported that CRV431 significantly decreased the extent of fibrosis, or scarring of the liver, in a second animal model of liver fibrosis. CRV431 is a clinical stage cyclophilin...

June 6, 2019

Developments

AnaptysBio presents updated Phase 2a data of etokimab in asthma

AnaptysBio (NASDAQ:ANAB) presented updated Phase 2a data of etokimab for the treatment of severe eosinophilic asthma at the European Academy of Allergy and Clinical Immunology congress. Etokimab is a humanized anti...

June 5, 2019

Developments

Helius Medical adds 3 PoNS clinics in Canada

Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) added three new clinics authorized to provide PoNS treatment in Canada, extending regional access to its innovative treatment.

June 5, 2019

Developments

ObsEva completes recruitment for Phase 3 trial of nolasiban

ObsEva (NASDAQ:OBSV) completed patient recruitment for its Phase 3 trial of nolasiban for the improvement of rates of pregnancy and live birth in patients undergoing assisted reproduction technology or in-vitro...

June 4, 2019

Author - Abby Hardy

Enanta Pharma reports topline results from Phase 2a RSV trial

Karyopharm Therapeutics reports new selinexor combination data in multiple myeloma

InflaRx treats first pyoderma gangraenosum patient in Phase 2a trial

ContraVir Pharma CRV431 data published in PLOS ONE

Helius Medical PoNS study on brain activity in peer-reviewed journal

vTv Therapeutics reports positive topline results from Phase 2 diabetes trial

ContraVir Pharma sets stage for CRV431 development in NASH with positive results in second model of liver fibrosis

AnaptysBio presents updated Phase 2a data of etokimab in asthma

Helius Medical adds 3 PoNS clinics in Canada

ObsEva completes recruitment for Phase 3 trial of nolasiban

Subscribe